- 中文名称
包柔氏螺旋体菌IgM Elisa试剂盒
- 英文名字
- Borrelien IgM ELISA Kit
- 供应商
- Biomedica Immunoassays
- 产品货号
- BI-21042
- 产品报价
- ￥12x8tests
- 产品说明书
- 点击查看
- 购买方式
- 90%产品中国有现货库存。银行转账、电汇、支票、现金，在线支付宝及网银支付，或直接与我们电话联系400-6800-868
- 产品新闻
- 背景资料
- Lyme borreliosis is a bacterial infection caused by the spirochete Borrelia Burgdorferi, Borrelia Afzelii and Borrelia Garinii and is the most vector-transmitted human disease in Europe. The spirochetal bacteria were first described and isolated in 1981 by Willi Burgdorfer in the tick Ixodes dammini in Montana (USA). The infection with Borrelia is characterized by a variety of clinical symptoms and can be divided into 3 stages:
Stage 1, early dermatitis, appearing days or weeks after the infection. Clinical: erythema migrans.
Stage 2, early disseminated infection, appears weeks to months after infection. Clinical: lymphocytic meningoradiculitis (Bannwarth's syndrome), neuroborreliosis.
Stage 3, late disseminated infection, occurring up to years after infection. Clinical: chronic progressive encephalomyelitis, acrodermatitis chronica atrophicans (ACA), chronic arthritis.
Antibiotic therapy is indicated in all stages of the disease. It shortens disease duration significantly, when instituted in stage 1. Diagnosis of the bacterial infection relies on the detection of specific IgM antibodies against Borrelia.
To ensure diagnostic specificity, the Borrelia IgM ELISA microwell strips are coated with the following Borellia-specific recombinant antigens:
p21 = OspC (outer surface protein C): B. afzellii (pKo), B. garinii (20047)
p41/I = (inner part of flagellin): B. bavariensis (pBi)
VIsE: fusion proteins of different Borrelia genospecies
Many features of later infection are not specific to Lyme Borreliosis and occur in other conditions. The diagnosis of Lyme Borreliosis should be made only after careful evaluation of the patient´s clinical history, physical findings, laboratory evidence and exposure risk evaluation.
- 产品描述
- Method
Indirect ELISA, HRP/TMB, 12×8-well detachable strips
Sample type
Serum, plasma and CSF
Sample volume
10 µl / sample (serum and plasma), 100 µl / sample (CSF)
Assay time
1 h / 30 min / 15 min
Standard range
0 – 30 BBU/ml (Biomedica Borrelia Units)
Sensitivity
100% (serum)
82% (CSF)
Cross-reactivity
The assay works with human samples only.
Specificity
Endogenous and recombinant human anti-Borrelia IgM (B. burgdoreri ss, B. afzelii, B. garnii, B. bavariensis)
- 产品特点
- 保存建议
- +4°C
- 其他
- Biomedica Immunoassay(bmgrp)公司成立于1988年, 总部位于奥地利维也纳，主要致力于研究、开发和生产基于ELISA方法用于临床前研究相关标记物检测的工具。迄今为止Biomedica Immunoassay公司在心血管检测及骨代谢检测领域开发了一系列特色ELISA检测试剂盒，Biomedica Immunoassay的生产过程符合GMP/GLP指南，并符合ISO 9001:2015管理体系，有CE认证。Biomedica Immunoassay的产品根据FDA， EMEA和ICH指南进行验证，并具有验证报告。
-
- 注意
-
该页面的中文产品信息的翻译，仅供参考。准确的产品信息请以厂家的英文说明书为准。下单前，请浏览说明书确认。
-
